Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Apr 05, 2017 2:12pm
139 Views
Post# 26080917

RE:RE:CHINA TRIAL STATUS?

RE:RE:CHINA TRIAL STATUS?Toniv,

As part of the Hepalink deal, and as listed in Resverlogix corporate documents, "Hepalink will be responsible for all clinical and development costs in the Territories, including a patient population that is expected to be included in the Company’s Phase 3 BETonMACE trial."

Most of the talk has been about Taiwan, however the Taiwan launch seems to keep getting pushed back. At the Q2 2016 update we were told that Taiwan BETonMACE involvement should be launching by end of 2016. At the December 2016 update we were told that Taiwan will begin recruiting in Q1 2017. The latest Zacks report listed that BETonMACE study sites in Taiwan, China and Russia are anticipated to open in June. So it seems that Taiwan and other sites will come on board BETonMACE soon.

BearDownAZ




Bullboard Posts